血清可溶性CD16水平与骨髓瘤分期的相关性：214份血清研究

[Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums].

作者信息

Mathiot C, Grosbois B, Teillaud J L, Tartour E, Mosseri V, Euller-Ziegler L, Daragon A, Michaux J L, Facon T, Bernard J F

机构信息

Unité Inserm U255 et Département de biologie clinique, Institut Curie, Paris.

出版信息

Rev Med Interne. 1993;14(10):960. doi: 10.1016/s0248-8663(05)80078-5.

DOI:10.1016/s0248-8663(05)80078-5

PMID:8009056

Abstract

Soluble CD16 (sCD16) are soluble part of Fc receptor for IgG which control in mice, proliferation of hybridoma B cells and IgG production. The levels of sCD16 in 165 myeloma patients and 29 patients with MGUS appear significantly different:25a.u./ml versus 144a.u./ml and values of stage I are significantly higher than those of stages II + III.sCD16 might be a prognosis factor in myeloma.

摘要

可溶性CD16（sCD16）是IgG的Fc受体的可溶性部分，在小鼠中可控制杂交瘤B细胞的增殖和IgG的产生。165例骨髓瘤患者和29例意义未明的单克隆丙种球蛋白病（MGUS）患者的sCD16水平存在显著差异：分别为25个任意单位/毫升和144个任意单位/毫升，且I期的值显著高于II + III期。sCD16可能是骨髓瘤的一个预后因素。